The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 361-367

  Zhang, Yang Yang ^a   Xie, Ke Ming ^a   Yang, Guo Qing ^b   Mu, Hui Jun ^c   Yin, Ying ^c   Zhang, Bin ^c   Xie, Ping ^c  

^a SOOCHOW UNIVERSITY   (China)

^b Xi'an Central Hospital   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Glucosylceramide synthase; Leukemia cell; MDR1 gene; P glycoprotein function; Rhodamine123; RNA interfering

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GLUCOSYLTRANSFERASES; HUMANS; K562 CELLS; LEUKEMIA; P-GLYCOPROTEIN; RNA, SMALL INTERFERING;

EID: 79955790026     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0798-7     Document Type: Article

References (20)

1. Friedenberg WR, Tallman MS, Brodsky I, Paietta E, Rowe JM, Lee SJ, Rowland Jr KM, Schnetzer GW, Reed JC. Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res. 2004;28(8):813-9.
2. Carrion C, Madariaga MA, Domingo JC. In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34+ leukemic cells. Life Sci. 2004;75(3):313-28.
3. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40(7):S13-9.
4. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84(9):3004-8.
5. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427. (Pubitemid 23237876)
6. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Wahrer DC, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Lowenberg B, Schuurhuis GJ, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood. 1996;87(11):4809-16. (Pubitemid 26162383)
7. Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in childhood hematologic malignancies. J Med Invest. 2003;50(3):126-35. (Pubitemid 38019759)
8. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 1993; 81(9):2215-11.
9. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levada T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int Cancer. 2001;94(2):157-65. (Pubitemid 32911407)
10. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther. 2004;3(5):633-9. (Pubitemid 39193742)
11. Liu YY, Han TY, Giuliano AE, Hansen N, Myles C. Cabot Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem. 2000;275(10):7138-43. (Pubitemid 30146262)
12. Ping X, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, Mu HJ, Zhang B, Qiao WZ, Xie KM, et al. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res. 2008;32(3):475-80. (Pubitemid 351295915)
13. Ricci C, Onida F, Ghidoni R. Sphingolipid players in the leukemia arena. Biochim Biophys Acta. 2006;1758(12):2121-32. (Pubitemid 44879363)
14. Gouaze V, Liu YY, Carlton S, Prickett CS, Jing Y, Giuliano AE, Myles C, et al. Cabot glucosylceramide synthase blockade downregulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 2005;65(9):3861-7. (Pubitemid 40616367)
15. Liu Y, Xie KM, Yang GQ, Bai XM, Shi YP, Mu HJ, Qiao WZ, Bin Zhang B, Xie P. GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line. Cancer Chemother Pharmacol. 2009;66(3):433-9.
16. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152-62.
17. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K, et al. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta. 2000;1485(2-3):63-99. (Pubitemid 30314727)
18. Kohyama-koganaya A, Hirabayashi Y. Role of glucosylceramide synthase as negative regulator for ceramide. Tanpakushitsu Kakusan Koso. 2002;47(4 Suppl):470-5.
19. Gerrard G, Butters TD, Ganeshaguru K, Mehta AB. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur J Pharmacol. 2009;609(1-3):34-9.
20. De Rosa MF, Sillence D, Ackerley C, Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J Biol Chem. 2004;279(9):7867-76. (Pubitemid 38294673)